These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 21782251)

  • 21. Repositioning of diabetes treatments for depressive symptoms: A systematic review and meta-analysis of clinical trials.
    Moulton CD; Hopkins CWP; Ismail K; Stahl D
    Psychoneuroendocrinology; 2018 Aug; 94():91-103. PubMed ID: 29775878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study.
    Jefferson JW; Rush AJ; Nelson JC; VanMeter SA; Krishen A; Hampton KD; Wightman DS; Modell JG
    J Clin Psychiatry; 2006 Jun; 67(6):865-73. PubMed ID: 16848645
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lisdexamfetamine dimesylate augmentation for adults with major depressive disorder and inadequate response to antidepressant monotherapy: Results from 2 phase 3, multicenter, randomized, double-blind, placebo-controlled studies.
    Richards C; McIntyre RS; Weisler R; Sambunaris A; Brawman-Mintzer O; Gao J; Geibel B; Dauphin M; Madhoo M
    J Affect Disord; 2016 Dec; 206():151-160. PubMed ID: 27474961
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Pioglitazone effects on blood pressure in patients with metabolic syndrome].
    Takahashi A; Kushiro T
    Nihon Rinsho; 2008 Aug; 66(8):1591-5. PubMed ID: 18700562
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cariprazine Augmentation to Antidepressant Therapy in Major Depressive Disorder: Results of a Randomized, Double-Blind, Placebo-Controlled Trial.
    Earley WR; Guo H; Németh G; Harsányi J; Thase ME
    Psychopharmacol Bull; 2018 Jun; 48(4):62-80. PubMed ID: 30618475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Adjunctive Brexpiprazole in Patients With Major Depressive Disorder and Irritability: An Exploratory Study.
    Fava M; Ménard F; Davidsen CK; Baker RA
    J Clin Psychiatry; 2016 Dec; 77(12):1695-1701. PubMed ID: 27379823
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Duloxetine for the treatment of major depressive disorder: safety and tolerability associated with dose escalation.
    Wohlreich MM; Mallinckrodt CH; Prakash A; Watkin JG; Carter WP
    Depress Anxiety; 2007; 24(1):41-52. PubMed ID: 16845641
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Telomere length as a predictor of response to Pioglitazone in patients with unremitted depression: a preliminary study.
    Rasgon N; Lin KW; Lin J; Epel E; Blackburn E
    Transl Psychiatry; 2016 Jan; 6(1):e709. PubMed ID: 26731446
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
    Trivedi MH; Thase ME; Fava M; Nelson CJ; Yang H; Qi Y; Tran QV; Pikalov A; Carlson BX; Marcus RN; Berman RM
    J Clin Psychiatry; 2008 Dec; 69(12):1928-36. PubMed ID: 19192475
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Minocycline as an adjunct for treatment-resistant depressive symptoms: A pilot randomised placebo-controlled trial.
    Husain MI; Chaudhry IB; Husain N; Khoso AB; Rahman RR; Hamirani MM; Hodsoll J; Qurashi I; Deakin JF; Young AH
    J Psychopharmacol; 2017 Sep; 31(9):1166-1175. PubMed ID: 28857658
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of levomilnacipran sustained release in moderate to severe major depressive disorder: a randomized, double-blind, placebo-controlled, proof-of-concept study.
    Montgomery SA; Mansuy L; Ruth A; Bose A; Li H; Li D
    J Clin Psychiatry; 2013 Apr; 74(4):363-9. PubMed ID: 23656841
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study Group.
    Einhorn D; Rendell M; Rosenzweig J; Egan JW; Mathisen AL; Schneider RL
    Clin Ther; 2000 Dec; 22(12):1395-409. PubMed ID: 11192132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The efficacy and safety of aripiprazole as adjunctive therapy in major depressive disorder: a multicenter, randomized, double-blind, placebo-controlled study.
    Berman RM; Marcus RN; Swanink R; McQuade RD; Carson WH; Corey-Lisle PK; Khan A
    J Clin Psychiatry; 2007 Jun; 68(6):843-53. PubMed ID: 17592907
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Adjunctive low-dose aripiprazole with standard-dose sertraline in treating fresh major depressive disorder: a randomized, double-blind, controlled study.
    Lin CH; Lin SH; Jang FL
    J Clin Psychopharmacol; 2011 Oct; 31(5):563-8. PubMed ID: 21869699
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Duloxetine 60 mg once-daily in the treatment of painful physical symptoms in patients with major depressive disorder.
    Brannan SK; Mallinckrodt CH; Brown EB; Wohlreich MM; Watkin JG; Schatzberg AF
    J Psychiatr Res; 2005 Jan; 39(1):43-53. PubMed ID: 15504423
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of pioglitazone on plasma ceramides in adults with metabolic syndrome.
    Warshauer JT; Lopez X; Gordillo R; Hicks J; Holland WL; Anuwe E; Blankfard MB; Scherer PE; Lingvay I
    Diabetes Metab Res Rev; 2015 Oct; 31(7):734-44. PubMed ID: 25959529
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Escitalopram for severe asthma and major depressive disorder: a randomized, double-blind, placebo-controlled proof-of-concept study.
    Brown ES; Howard C; Khan DA; Carmody TJ
    Psychosomatics; 2012; 53(1):75-80. PubMed ID: 22221724
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Efficacy of risperidone augmentation to antidepressants in the management of suicidality in major depressive disorder: a randomized, double-blind, placebo-controlled pilot study.
    Reeves H; Batra S; May RS; Zhang R; Dahl DC; Li X
    J Clin Psychiatry; 2008 Aug; 69(8):1228-1236. PubMed ID: 18681749
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study.
    Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC
    Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Efficacy and safety of adjunctive cariprazine in inadequate responders to antidepressants: a randomized, double-blind, placebo-controlled study in adult patients with major depressive disorder.
    Durgam S; Earley W; Guo H; Li D; Németh G; Laszlovszky I; Fava M; Montgomery SA
    J Clin Psychiatry; 2016 Mar; 77(3):371-8. PubMed ID: 27046309
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.